Irland - engelsk - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - daptomycin - powder for solution for injection/infusion - 350 milligram(s) - other antibacterials; daptomycin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - daptomycin - powder for solution for injection/infusion - 500 milligram(s) - other antibacterials; daptomycin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - daptomycin - powder for solution for injection/infusion - 350 milligram(s) - other antibacterials; daptomycin

USA - engelsk - NLM (National Library of Medicine)

jiangsu hengrui medicine co., ltd. - daptomycin (unii: nwq5n31vkk) (daptomycin - unii:nwq5n31vkk) - daptomycin for injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes, streptococcus agalactiae, streptococcus dysgalactiae subsp. equisimilis, and enterococcus faecalis (vancomycin-susceptible isolates only). pediatric use information is approved for merck & co., inc.’s cubicin (daptomycin for injection). however, due to merck & co., inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. daptomycin for injection is indicated for the treatment of adult patients with staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. pediatric use information is approved for merck & co., inc.’s cubicin (daptomyci

Irland - engelsk - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - daptomycin - powder for solution for injection/infusion - 350 milligram(s) - other antibacterials; daptomycin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - daptomycin - powder for solution for injection/infusion - 500 milligram(s) - other antibacterials; daptomycin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - daptomycin - powder for solution for injection/infusion - 500 milligram(s) - other antibacterials; daptomycin

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - daptomycin, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide - daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s). consideration should be given to official guidance on the appropriate use of antibacterial agents. daptomycin is not indicated for the treatment of pneumonia.,adult patients (18 years of age and over),1. complicated skin and skin structure infections cubicin is indicated for the treatment of adults (18 years of age and over) with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,2. staphylococcus aureus bloodstream infections (bacteraemia) cubicin is indicated in adults (18 years of age and over) for staphylococcus aureus bloodstream infections (bacteraemia), in

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - daptomycin, quantity: 350 mg - injection, powder for - excipient ingredients: sodium hydroxide - daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s). consideration should be given to official guidance on the appropriate use of antibacterial agents. daptomycin is not indicated for the treatment of pneumonia.,adult patients (18 years of age and over) 1. complicated skin and skin structure infections cubicin is indicated for the treatment of adults (18 years of age and over) with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,2. staphylococcus aureus bloodstream infections (bacteraemia) cubicin is indicated in adults (18 years of age and over) for staphylococcus aureus bloodstream infections (bacteraemia), inc

USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - daptomycin (unii: nwq5n31vkk) (daptomycin - unii:nwq5n31vkk) - daptomycin for injection is indicated for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes, streptococcus agalactiae, streptococcus dysgalactiae subsp. equisimilis, and enterococcus faecalis (vancomycin-susceptible isolates only). daptomycin for injection is indicated for the treatment of adult patients with staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. daptomycin for injection is indicated for the treatment of pediatric patients (1 to 17 years of age) with staphylococcus aureus bloodstream infections (bacteremia). daptomycin for injection is not indicated for the treatment of pneumonia. daptomycin for injection is not i